Early Prediction of Therapy Response in Acute Myeloid Leukemia
Author Information
Author(s): Susanne Mueller, Stefan Holdenrieder, Petra Stieber, Torsten Haferlach, Andreas Schalhorn, Jan Braess, Dorothea Nagel, Dietrich Seidel
Primary Institution: Institute of Clinical Chemistry, University Hospital Munich-Grosshadern
Hypothesis
Can nucleosomal DNA fragments in serum predict therapy response in patients with acute myeloid leukemia?
Conclusion
Nucleosomal DNA fragments are valuable markers for early prediction of therapeutic efficacy in patients with acute myeloid leukemia.
Supporting Evidence
- Nucleosomal DNA levels decreased in almost all patients during the first week of chemotherapy.
- Patients with complete remission had higher nucleosomal DNA levels compared to those with insufficient response.
- The area under the curve of nucleosomal DNA values significantly discriminated between complete responders and non-responders.
Takeaway
Doctors can check a type of DNA in the blood to see if leukemia treatment is working early on.
Methodology
The study measured nucleosomal DNA, thymidine kinase, lactate dehydrogenase, and leukocytes in serum samples from 25 patients during chemotherapy.
Limitations
The study had a small sample size and limited demographic diversity.
Participant Demographics
{"median_age":62,"gender_distribution":{"female":12,"male":13}}
Statistical Information
P-Value
0.017
Statistical Significance
p = 0.017
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website